1 unchanged sentence
Rule 10b5-1 Trading Arrangements and Non-Rule 10b5-1 Trading Arrangements
−Removed: During the three months ended March 31, 2025 , none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
+Added: During the three months ended June 30, 2025 , none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted , modified or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (as each term is defined in Item 408 of Regulation S-K).
EXHIBIT INDEX
Amended and Restated Certificate of Incorporation.
+Added: Certificate of Amendment of the Amended and Restated Certificate of Incorporation
Amended and Restated Bylaws.
−Removed: Release Agreement, dated April 24, 2025, by and between the Company and Christopher G.
−Removed: Waiver, dated February 18, 2025, by and between the Company and Orbimed Royalty & Credit Opportunities IV, LP.
+Added: Sixth Amendment and Waiver to Credit Agreement dated as of June 10, 2025, by and between the Company and OrbiMed Royalty & Credit Opportunities IV, LP.
+Added: Second Amendment to Collaboration and License Agreement, dated as of June 27, 2025, by and between the Company and Torii Pharmaceuticals Co., Ltd.
Certification of Chief Executive Officer and President (Principal Executive Officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
7 unchanged sentences
333-225104), filed with the Securities and Exchange Commission on May 22, 2018.
+Added: (2) Previously filed as Exhibit 3.1 to the Company's Current Report on Form 8-K (File No.
+Added: 001-38529), filed with the Securities and Exchange Commission on July 23, 2025.
(3) Previously filed as Exhibit 3.4 to the Company's Registration Statement on Form S-1 (File No.
333-225104), filed with the Securities and Exchange Commission on May 22, 2018.
−Removed: (3) Previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-38529), filed with the Securities and Exchange Commission on April 25, 2025.
+Added: + Certain portions of this exhibit, indicated by asterisks, have been omitted pursuant to Item 601(b)(10) of Regulation S-K because they are not material and would likely cause competitive harm to the registrant if publicly disclosed.
+Added: Pursuant to Item 601(a)(5) of Regulation S-K promulgated by the SEC, certain exhibits and schedules to this agreement have been omitted.
+Added: The Company hereby agrees to furnish supplementally to the SEC, upon its request, any or all of such omitted exhibits or schedules.
* These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C.
2 unchanged sentences
VERRICA PHARMACEUTICALS INC.
+Added: August 12, 2025
/s/ Jayson Rieger
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.